SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMedReports FDA Calendar: Seven Laggard Trades
LLY
|
|
|
+8.05%
in
158 days
Below are seven companies from the <font> BioMedReports.com FDA Calendar </font> database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yahoo! Finance on 6/17/09 during late day trading. <> <font> <>http...
|
FDA, Clinical Trial Updates: GENZ, HGSI, LLY, NGSX
LLY
|
|
|
-3.44%
in
27 days
(closed on 06/17/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions...
|
Eli Lilly and Co (New York Stock Exchange)
LLY
|
|
|
+7.24%
in
216 days
http://www.lilly.com/ <> Eli Lilly and Company, incorporated in 1901, discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. It<><><><><><><><><><><><><><>...
|
Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX
LLY
|
|
|
+6.07%
in
41 days
(closed on 05/21/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
Updated Clinical Trial and FDA Decision Calendars
LLY
|
|
|
+15.74%
in
37 days
(closed on 04/10/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
From the Blogosphere
AstraZeneca Seeks FDA Approval – Analyst Blog
|
|
|
Recently, AstraZeneca plc (AZN) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its blood clot preventer Brilinta (ticagrelor). Brilinta is an oral reversible P2Y12 adenosine diphosphate receptor antagonist for arterial thrombosis aimed to compete with the blockbuster drug Plavix which is co-developed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY). On Oct 26, 2009, AstraZeneca filed for approval of the drug with the European Medicines Agency (EMEA) and is awaiting validation of the application.
AstraZeneca is seeking an FD...
|
Bristol Divests Nutritional Segment – Analyst Blog
|
|
|
Bristol-Myers Squibb Co. (BMY) intends to split its 83.1% holding in the Nutritional segment which operates under its subsidiary Mead Johnson and develops infant formulas such as Enfamil and other nutritional products. The move is aimed to enable the company to concentrate on its core biopharmaceutical business. The transaction is expected to be accretive to earnings beginning in 2010.
Under the terms of the deal, Bristol-Myers shareholders can exchange some, none or all of their shares of the company for shares of Mead Johnson common stock tax-free and at a discount. On completion, the ex...
|
Big Pharma & Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma & Biotech – Zacks Analyst Interviews
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Big Pharma and Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
|
|
|
|
Andy
(+385.03% risk: conservative)
|
|
|
|
|
|
|
Andy
(+385.03% risk: conservative)
|
|
|
More Resources
|
About Eli Lilly and Company
- Answers.com
